Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


NICE recommendations for ulcerative colitis

The National Institute for Health and Care Excellence (NICE) has recommended Remicade (infliximab; Merck Sharp & Dohme), Humira (adalimumab; Abbvie) and Simponi (golimumab; Merck Sharp & Dohme), within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. Simponi is recommended only if Merck Sharp & Dohme provides the 100mg dose at the same cost as the 50mg dose, as agreed in the patient access scheme.

Additionally, NICE recommends Remicade as an option for treating severely active ulcerative colitis in children and young people aged 6–17 years with the same conditions as above.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067435

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.